European Commission Approves Darzalex®
(WorldNews Health)

Daratumumab-VTd is the first regimen approved in over six years for newly diagnosed patients who are eligible for a stem cell transplant[1] Approval is based on data from the Phase 3 CASSIOPEIA trial, which demonstrated that the addition of daratumumab resulted in deeper response rates and improved progression-free survival (PFS) compared to VTd alone[2] Daratumumab has been used to treat more than 100,000 patients worldwide[3] This is the sixth approval for daratumumab and the third in the frontline setting[4] BEERSE, BELGIUM, 20 January 2020 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has granted marketing...